Executive Summary / Key Takeaways

• Absci has successfully transitioned to a clinical-stage biotech company with the initiation of its Phase 1 trial for ABS-101, an anti-TL1A antibody for IBD, validating its Integrated Drug Creation platform's ability to advance AI-designed candidates.
• The company's AI platform, combining generative AI with a synthetic biology wet lab, offers quantifiable advantages, including claims of significantly shortened discovery timelines (up to 50% faster) and the ability to design antibodies to difficult-to-drug targets and optimize multiple characteristics simultaneously.
• Absci is strategically evolving its business model to prioritize a balanced portfolio of high-value internal programs (like ABS-101 and the promising ABS-201 for androgenic alopecia) and selective co-development/drug creation partnerships, moving away from a volume-based partnership metric.
• Recent financial results for Q1 2025 show increased R&D investment (+34% year-over-year) driven by internal pipeline advancement, supported by recent capital raises (AMD PIPE, ATM) extending the cash runway into the first half of 2027.
• Upcoming catalysts include interim Phase 1 data for ABS-101 in the second half of 2025, ABS-201 Phase 1 initiation in early 2026 with potential interim efficacy data later that year, and anticipated new large pharma partnerships.

The Dawn of AI-Driven Drug Creation

Absci Corporation is positioning itself at the forefront of a transformative shift in biopharmaceutical discovery, aiming to create better biologics faster through the power of artificial intelligence. Founded in 2011 and becoming a public entity in 2021, the company has evolved from a technology development focus to a data-first generative AI drug creation enterprise. Its core mission is to leverage its unique Integrated Drug Creation platform to overcome the inherent challenges and inefficiencies of traditional biologic drug discovery.

The broader biologics market represents a significant and growing medical opportunity, yet bringing these complex medicines to patients remains a costly and time-consuming endeavor. Absci's strategy directly addresses this bottleneck by applying AI to streamline and enhance the entire process, from target identification and antibody design to preclinical validation and manufacturing optimization. This approach seeks to shorten the time to clinic and increase the probability of success for new therapeutic candidates.

The competitive landscape in AI-driven drug discovery is dynamic and includes companies like Schrödinger (SDGR), Exscientia (EXAI), Recursion Pharmaceuticals (RXRX), and Relay Therapeutics (RLAY). While these competitors also utilize AI, their approaches and focus areas can differ. Some may focus more heavily on computational simulations (like SDGR), small molecule design (like EXAI), or leveraging vast data sets (like RXRX). Absci differentiates itself with an integrated approach that tightly couples AI design with a high-throughput synthetic biology wet lab, specifically tailored for biologics. This integration is central to its competitive positioning.

The Integrated Platform: Absci's Technological Engine

At the heart of Absci's strategy is its Integrated Drug Creation platform. This proprietary technology combines advanced generative AI models with a synthetic biology data engine and wet lab validation capabilities. The platform operates on a continuous feedback loop: AI models design antibody candidates, the wet lab generates vast amounts of proprietary data through high-throughput screening, and this data is then fed back to train and refine the AI models. This "lab in the loop" process is designed to accelerate learning and improve the accuracy and generalizability of the models.

The platform offers several key technological differentiators. It enables de novo antibody design, allowing the creation of entirely new antibody sequences from scratch, even for difficult-to-drug epitopes where no known binders exist. The collaboration with Caltech on designing antibodies to the HIV caldera region, a previously untargeted epitope, serves as a notable example of this capability. The platform also facilitates multi-parametric lead optimization, allowing simultaneous optimization of multiple desired antibody characteristics beyond just binding affinity, such as developability, stability, and immunogenicity.

Specific, quantifiable benefits highlighted by the company underscore the platform's potential. The "lab in the loop" process is claimed to enable rapid iteration, potentially going from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Preclinical data for internal programs demonstrate tangible advantages: ABS-101 showed a 2x to 3x extended half-life and increased biodistribution in non-human primates compared to clinical-stage competitors, along with in vitro data suggesting lower immunogenicity risk. ABS-201 NHP data indicated excellent subcutaneous bioavailability (>90%) and supports high concentration formulation potential (>150 mg/ml), facilitating convenient dosing. These capabilities are designed to translate into faster development timelines, reduced costs, and potentially higher success rates compared to traditional methods.

Absci continues to invest in enhancing its technological edge through strategic R&D and collaborations. The partnership with AMD (AMD) aims to optimize compute solutions for complex biological modeling, accelerating in silico antibody design and evaluation. Collaborations like those with Twist Bioscience (TWST) (for DNA synthesis and validation) and Owkin (for AI target discovery) seek to integrate complementary expertise and technologies into the platform workflow, expanding its capabilities upstream into target identification and accelerating downstream validation. These technological advancements and strategic partnerships are intended to strengthen Absci's competitive moat, enable the creation of highly differentiated assets, and drive value creation for both internal programs and partners.

Evolving Business Model and Strategic Focus

Absci's business model is undergoing a strategic evolution, shifting from a primary focus on generating revenue through fee-based drug creation partnerships to building a balanced portfolio that includes high-value proprietary internal programs and co-development arrangements. While traditional partnerships remain a component, the company is now prioritizing selective collaborations that offer synergistic expertise or leverage the platform for challenging targets, rather than simply pursuing a high volume of deals.

The rationale for this shift is multifaceted. Developing internal programs allows Absci to retain greater control and potentially capture more significant economic returns upon successful out-licensing or sale after key value inflection points (from preclinical proof of concept through Phase 2 clinical proof of concept). This also serves as crucial validation for the Integrated Drug Creation platform. Co-development partnerships, such as the multi-program collaboration with Memorial Sloan Kettering Cancer Center, offer risk and cost sharing while leveraging external expertise, particularly in areas like novel target validation in oncology. This diversified approach aims to balance potential high rewards with shared risks.

Revenue currently consists primarily of partner program revenue derived from upfront fees, research fees, and project-based milestones from drug creation agreements. In Q1 2025, partner program revenue increased by 31% year-over-year to $1.179 million, driven by the timing and mix of ongoing program activity. However, revenue remains concentrated, with two partners accounting for approximately 95% of revenue in Q1 2025. This concentration highlights a dependency risk inherent in the current revenue model, which the strategic diversification aims to mitigate over time by creating alternative value streams from internal assets.

Pipeline Progress and Financial Performance

Absci's internal pipeline is a key focus of its evolving strategy. The company has identified four wholly-owned programs, with an initial focus on cytokine biology and oncology:

• ABS-101: A potential best-in-class anti-TL1A antibody for Inflammatory Bowel Disease (IBD). This program recently achieved a significant milestone by initiating its first-in-human Phase 1 clinical trial in May 2025, officially making Absci a clinical-stage company. Preclinical data supports its potential for longer dosing intervals (8-12 weeks) and subcutaneous administration, addressing limitations of current IBD treatments. Interim clinical readout is anticipated in the second half of 2025, focusing on safety, tolerability, PK, PD, and immunogenicity. The company is also exploring a potential first-in-class bispecific antibody incorporating ABS-101 and a novel, difficult-to-drug target.
• ABS-201: A potential groundbreaking anti-prolactin receptor antibody for androgenic alopecia (AGA), or male and female pattern hair loss. This indication represents a large market with significant unmet need and limited innovation in decades. ABS-201 is being developed for durable, effective hair regrowth. Preclinical development is ongoing, with a potential regulatory filing in the first half of 2026 and Phase 1 trial initiation expected in early 2026. Interim efficacy data from the Phase 1 trial is anticipated in the second half of 2026. Given its market potential and straightforward clinical path, Absci plans to develop ABS-201 internally through later-stage clinical development and proof of concept.
• ABS-301: A potential first-in-class antibody targeting an undisclosed immuno-oncology target identified via Absci's reverse immunology platform. Early data indicates potential broad applicability, including in squamous cell carcinomas. Mode-of-action validation studies are ongoing, with a development candidate nomination expected after ongoing in vivo studies.
• ABS-501: A potential best-in-class AI-designed anti-HER2 antibody for oncology. Preclinical data shows novel epitope interactions, affinity comparable or superior to trastuzumab, and efficacy against trastuzumab-resistant tumors.

Financially, Absci continues to operate at a loss as it invests heavily in R&D and platform development. For the three months ended March 31, 2025, the net loss was $26.346 million, compared to $21.975 million in the prior-year period.

Operating expenses totaled $28.908 million in Q1 2025, an 18% increase from $24.396 million in Q1 2024. This increase was primarily driven by a 34% rise in Research and Development expenses to $16.364 million, reflecting the advancement of internal programs, including external preclinical development costs for ABS-101, and increased personnel and stock-based compensation. Selling, general, and administrative expenses also increased by 8% to $9.472 million, mainly due to higher stock-based compensation and administrative costs.

As of March 31, 2025, Absci held $134 million in cash, cash equivalents, and short-term investments, compared to $112.4 million at the end of 2024. The company's accumulated deficit stood at $535.9 million. Recent financing activities, including a $20 million PIPE investment from AMD in January 2025 and approximately $20 million raised through its ATM facility since the end of 2024, have bolstered the balance sheet.

Outlook and Risks

Management guidance indicates that existing cash, cash equivalents, and short-term investments are expected to be sufficient to fund operations into the first half of 2027. This forecast is based on the current strategic plan, which includes significant investment in advancing the internal pipeline. Potential upside to this cash runway could come from non-dilutive cash inflows generated by new platform collaborations with large pharmaceutical companies or asset transactions involving wholly-owned programs like ABS-101.

Key catalysts anticipated in the near to medium term include the interim Phase 1 data readout for ABS-101 in the second half of 2025, the initiation of the ABS-201 Phase 1 trial in early 2026, and potential interim efficacy data for ABS-201 in the second half of 2026. The company also anticipates signing one or more new large pharma partnerships for drug creation collaborations this year, which would further validate the platform and potentially provide additional funding.

Investing in Absci involves significant risks, typical of early-stage biotech companies leveraging novel technologies. The company has a limited operating history and has incurred substantial losses, with no guarantee of achieving profitability. Future capital raises may be necessary and could result in stockholder dilution or restrictive debt covenants. Biologic drug development is inherently uncertain, and there is no assurance that internal or partnered programs will successfully advance through clinical trials, receive regulatory approval, or be commercialized. Reliance on third parties for preclinical studies, clinical trials, and manufacturing poses operational risks. The highly competitive landscape includes larger, better-financed companies with established resources and market positions. The novelty of Absci's AI platform could lead to market skepticism or regulatory challenges. Intellectual property protection is critical but complex and subject to risks of challenge or infringement. Furthermore, the company's dependence on its IT systems and computational resources, as well as broader macroeconomic and regulatory uncertainties (including those related to AI and the FDA), could adversely impact operations and financial performance.

Conclusion

Absci stands at a pivotal juncture, having successfully translated its AI-driven drug creation capabilities into a clinical-stage asset with ABS-101 entering Phase 1. This milestone, coupled with the promising preclinical profile of ABS-201 and a pipeline of other AI-designed candidates, underscores the potential of its Integrated Drug Creation platform. The strategic shift towards building a balanced portfolio of high-value internal programs and selective partnerships, while moving away from a volume-centric approach, reflects a focus on maximizing return on investment and diversifying risk.

While the company faces significant challenges, including substantial operating losses, the need for future capital, and the inherent uncertainties of drug development and commercialization in a competitive market, its differentiated technology offers a potential competitive edge. The ability to rapidly design and optimize biologics for desirable characteristics, including addressing difficult targets, could attract high-quality partners and drive the value of its proprietary pipeline. Investors should closely monitor the upcoming clinical data readouts for ABS-101 and ABS-201, the progress in securing new large pharma collaborations, and the company's cash utilization as key indicators of its ability to execute on its strategy and realize the potential of its AI-powered approach to drug creation.